mecasermin IGF-1
Selected indexed studies
- Gut Microbiota and IGF-1. (Calcif Tissue Int, 2018) [PMID:29362822]
- Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment. (Stem Cell Rev Rep, 2023) [PMID:36269524]
- Mecasermin. (BioDrugs, 2008) [PMID:18481900]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Gut Microbiota and IGF-1. (2018) pubmed
- Mecasermin. (2008) pubmed
- Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. (2008) pubmed
- Mecasermin for the treatment of Rett Syndrome: a systematic review. (2025) pubmed
- Mecasermin (recombinant human insulin-like growth factor I). (2009) pubmed
- Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment. (2023) pubmed
- IGF-1 regulate the expression of uncoupling protein 2 via FOXO1. (2019) pubmed
- Insulin-like Growth Factor 1 (IGF-1) as a marker of cognitive decline in normal ageing: A review. (2018) pubmed
- Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. (2014) pubmed
- Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. (2009) pubmed